Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival, IDFS, versus trastuzumab emtansine, T-DM1, in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence. This is the second positive Phase III trial of ENHERTU in the HER2-positive early breast cancer setting following positive results from the DESTINY-Breast11 Phase III neoadjuvant trial earlier this year. Overall survival was not mature at the time of this planned interim analysis and will be assessed at a subsequent analysis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- DESTINY-Breast05 phase 3 trial delivers positive topline results
- AstraZeneca to harmonize global listing structure
- AstraZeneca Stock (AZN) Looking Perkier on U.S. and U.K. Dual Listing Plan
- Trump Weekly: President threatens new tariffs, announces TikTok deal
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz